Granulocyte colony-stimulating factor in established febrile neutropenia: A randomized study of pediatric patients

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1163-1170

  Mitchell, P L ^a   Morland, B ^a   Stevens, M C ^a   Dick, G ^a   Easlea, D ^a   Meyer, L C ^a   Pinkerton, C R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CILASTATIN PLUS IMIPENEM; FLUCLOXACILLIN; GENTAMICIN; PIPERACILLIN; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; HOSPITALIZATION; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031044740     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1163     Document Type: Article

References (25)

1. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323-1332, 1993
2. Maher DW, Lieschke GJ, Green M, et al: Filgrastim in patients with chemotherapy-induced febrile neutropenia. Ann Intern Med 121:492-501, 1994
3. Chessells JM, Bailey C, Richards SM: Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council Trial UKALLX. Lancet 345:143-148, 1995
4. Rolston KV, Berkey P, Bodey GP, et al: A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283-291, 1992
5. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. I. and II. N Engl J Med 327:28-35, 99-106, 1992
6. Metcalf D: The colony stimulating factors. Discovery, development, and clinical applications. Cancer 65:2185-2195, 1990
7. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
8. Lansky SB, List MA, Lansky LL, et al: The measurement of performance in childhood cancer patients. Cancer 60:1651-1656, 1987
9. Mayordomo JI, Rivera F, Diaz-Puente M, et al: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87:803-807, 1995
10. Bash RO, Katz JA, Cash JV, et al: Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74:189-196, 1994
11. Riikonen P, Saarinen UM, Makipernaa A, et al: Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double-blind placebo-controlled study in children. Paediatr Infect Dis J 13:197-202, 1994
12. Biesma B, de Vries EGE, Willemse PHB, et al: Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 26:932-936, 1990
13. Bodey GP, Anaissie E, Gutterman J, et al: Role of granulocyte-macrophage-colony stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis 13:18-22, 1994
14. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer (r-metHuG-CSF). N Engl J Med 325:164-170, 1991
15. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
16. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
17. Chevallier B, Chollet P, Merrouche Y, et al: Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13:1564-1571, 1995
18. Riikonen P, Rahiala J, Salonvaara M, et al: Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 13:289-294, 1995
19. Dibenedetto SP, Ragusa R, Ippolito AM, et al: Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: A randomised clinical trial. Eur J Haematol 55:93-96, 1995
20. Furman WL, Fairclough DL, Huhn RD, et al: Therapeutic effects and pharmacokinetics of human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 9:1022-1028, 1995
21. Saarinen UM, Hovi L, Riikonen P, et al: Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia. Med Pediatr Oncol 20:489-496, 1992
22. Marina NM, Shema SJ, Bowman LC, et al: Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumours treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol 23:328-334, 1994
23. Stevens MCG, Lewis IJ, Pinkerton CR: Use of rhGM-CSF to reduce the consequences of myelotoxicity in children receiving chemotherapy. Med Pediatr Oncol 25:248, 1995 (abstr)
24. Burdach SEG, Muschenich M, Josephs W, et al: Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumours. Cancer 76:510-516, 1995
25. Calderwood S, Romeyer F, Blanchette V, et al: Concurrent RhGM-CSF does not offset myelosuppression from intensive chemotherapy: Randomized placebo-controlled study in childhood acute lymphoblastic leukemia. Am J Hematol 47:27-32, 1994